Risk factors for hospital admissions associated with adverse drug events

Pharmacotherapy

Volumn 33, Issue 8, 2013, Pages 827-837

  Kongkaew, Chuenjid ^a,c   Hann, Mark ^a   Mandal, Jaydeep ^b   Williams, Steven D ^a,b   Metcalfe, David ^d   Noyce, Peter R ^a   Ashcroft, Darren M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c NARESUAN UNIVERSITY   (Thailand)

^d Wrightington Wigan and Leigh NHS Trust   (United Kingdom)

Author keywords

Adverse drug events; Adverse drug reactions; Hospital admissions; Preventable hospital admissions; Risk factor

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; AMLODIPINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BUMETANIDE; CLOPIDOGREL; CODEINE PHOSPHATE; DIHYDROCODEINE; DIURETIC AGENT; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; HYDROCORTISONE; INSULIN; LAMOTRIGINE; LISINOPRIL; METOLAZONE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PREDNISOLONE; SPIRONOLACTONE; UNINDEXED DRUG; URINARY TRACT AGENT; VALPROIC ACID; WARFARIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADRENAL CORTEX INSUFFICIENCY; ADULT; ADVERSE DRUG REACTION; AGE DISTRIBUTION; AGED; ANEMIA; ASCITES; BLEEDING; BRADYCARDIA; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIABETIC KETOACIDOSIS; DISEASE CONTROL; DIZZINESS; DROWSINESS; DRUG OVERDOSE; DRUG POTENTIATION; DUODENUM ULCER; EDEMA; ELECTROLYTE DISTURBANCE; ENURESIS; EPISTAXIS; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART RATE; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; MELENA; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; PHARMACEUTICAL CARE; PREDICTION; PRESCRIPTION; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; UNIVARIATE ANALYSIS; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; VOMITING;

EID: 84885221507     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1287     Document Type: Review

References (41)

1. Department of Health. An organisation with a memory: report of an expert group on learning from adverse event in the NHS. London: Stationary Office; 2000.
2. Institute of Medicine. To err is human: building a safer health system. Washington, D.C.: National Academies Press; 2000.
3. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007;41(9):1411-26.
4. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004;329(7456):15-9.
5. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42 (7):1017-25.
6. Stausberg J, Hasford J. Drug-related admissions and hospitalacquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. BMC Health Serv Res 2011;11(1):134.
7. Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother 2011;45(7-8):977-89.
8. Forster AJ, Asmis TR, Clark HD, et al. Ottawa hospital patient safety study: incidence and timing of adverse events in patients admitted to a Canadian teaching hospital. CMAJ 2004;170(8):1235-40.
9. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003;12(4):280-5.
10. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001;10(2):113-9.
11. Buajordet I, Wesenberg F, Brors O, Langslet A. Adverse drug events in children during hospitalization and after discharge in a Norwegian university hospital. Acta Paediatr 2002;91(1): 88-94.
12. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001;31 (4):199-205.
13. Honigman B, Lee J, Rothschild J, et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001;8(3):254-66.
14. Capuano A, Motola G, Russo F, et al. Adverse drug events in two emergency departments in Naples, Italy: an observational study. Pharmacol Res 2004;50(6):631-6.
15. Trifiro G, Calogero G, Ippolito FM, et al. Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiol Drug Saf 2005;14(5):333-40.
16. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274 (1):29-34.
17. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 1999;159(21):2553-60.
18. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions. Geneva: World Health Organization; 2002. Report No.: WHO/EDM/QSM/2002.2.
19. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore, MD: Johns Hopkins University Press, 1979: 1-7.
20. Anon. Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm 1998;55 (2):165-6.
21. Anon. MedDRA data retrieval and presentation: points to consider. Available from http://www.meddramsso.com/PTC/drp-ptc-r33.html 2012.
22. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990;228 (2):83-90.
23. The National Patient Safety Agency. Seven steps to patient safety for primary care. London: The National Patient Safety Agency; 2005.
24. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47(3):533-43.
25. Van Doormaal JE, Mol PG, Van den Bemt PM, et al. Reliability of the assessment of preventable adverse drug events in daily clinical practice. Pharmacoepidemiol Drug Saf 2008;17 (7):645-54.
26. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary, 63rd ed. London, UK: BMJ Publishing Group and Royal Pharmaceutical Society; 2012.
27. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296(15):1858-66.
28. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147(11):755-65.
29. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004;52(8):1349-54.
30. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36(12):1092-8.
31. Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992;33(1):61-8.
32. Holdsworth MT, Fichtl RE, Behta M, et al. Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc Med 2003;157(1):60-5.
33. Department of Health. Medicines and older people: implementing medicines-related aspects of the NSF for older people. London: Department of Health; 2001.
34. Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999;54(12):959-63.
35. Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet 2012;379(9823):1310-9.
36. Elliott RA, Barber N, Clifford S, Horne R, Hartley E. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Pharm World Sci 2008;30(1):17-23.
37. Pharmaceutical Services Negotiating Committee. New medicine service guidance. London: UK Department of Health; 2011.
38. Bednall R, McRobbie D, Hicks A. Identification of medication- related attendances at an A & E department. J Clin Pharm Ther 2003;28(1):41-5.
39. Lo A, Shalansky S, Leung M, Hollander Y, Raboud J. Patient characteristics associated with nonprescription drug use in intentional overdose. Can J Psychiatry 2003;48(4):232-6.
40. White AM, Hingson RW, Pan IJ, Yi H-Y. Hospitalizations for alcohol and drug overdoses in young adults ages 18-24 in the United States, 1999-2008: results from the nationwide inpatient sample. J Stud Alcohol Drugs 2011;72(5):774-86.
41. Zhan C, Arispe I, Kelley E, et al. Ambulatory care visits for treating adverse drug effects in the United States, 1995-2001. Jt Comm J Qual Patient Saf 2005;31(7):372-8.